StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.84−0.01 (-0.87%)

Close on Nov 18, 2026Market cap $65.27MP/E –Yield –

Cardiff Oncology, Inc. saw revenue fall 7.0% to $508.00K over the twelve months to Jun 30, 2026. Free cash flow was -$37.97M. At the latest close the market valued the company at $65.27M.

Revenue
$508.00K
-7.0% vs. a year earlier
Operating income
-$42.27M
TTM Q2 2026
Free cash flow
-$37.97M
FY2025
EPS, diluted
-$0.60
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$65.27M
P/E ratio
–
Price to sales
128.49
Price to book
2.46
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$508.00K
Net income
-$40.05M
EPS, diluted
-$0.60
Free cash flow
-$37.97M
Book value per share
$0.39
Diluted shares
68M

Trading

Previous close
$0.85
Open
$0.84
Day's range
$0.81 – $0.88
Volume
864,756
Average volume (20 days)
1,731,921
Beta (5 years)
1.58
52-week range
$0.71 – $3.31
RSI (14 days)
45.8
Volatility (1 year)
89.4%
Relative volume
0.75×
WACC
13.0%

Market cap history

Month-end market cap since 2012, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodCRDFS&P 500DifferenceCRDF per yearS&P 500 per year
1 month-6.9%-4.3%−2.6 pts
3 months-5.3%-4.6%−0.7 pts
Year to date-70.1%+7.9%−78.1 pts
1 year-58.9%+11.8%−70.7 pts
3 years-30.1%+68.0%−98.0 pts-11.2%+18.9%
5 years-86.5%+66.2%−152.7 pts-33.0%+10.7%
10 years-99.6%+291.3%−391.0 pts-43.1%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$508.00K-7.0% YoY

Gross profit

–

Operating income

-$42.27M

Net income

-$40.05M

EPS, diluted

-$0.60

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Cardiff Oncology filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Cardiff Oncology

Biological Products, (No Diagnostic Substances)

The company is a clinical-stage biotechnology firm that develops cancer therapies by targeting polo-like kinase 1 inhibition. It operates in a single business segment dedicated to oncology drug development. Its primary drug candidate is onvansertib, an oral small-molecule inhibitor tested in combination with standard medical treatments. The company focuses clinical programs on patients diagnosed with various malignancies, including RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple-negative breast cancer, and chronic myelomonocytic leukemia.

Company profile, executives and history

Cardiff Oncology stock: common questions

What is Cardiff Oncology's stock price?

CRDF closed at $0.84 on Nov 18, 2026, down 0.87% on the day. Over the past 52 weeks it traded between $0.71 and $3.31.

What is Cardiff Oncology's market cap?

Cardiff Oncology was worth $65.27M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is CRDF's P/E ratio?

Cardiff Oncology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.60), so it has no meaningful P/E ratio.

How much revenue does Cardiff Oncology make?

Cardiff Oncology reported revenue of $508.00K for the twelve months to Jun 30, 2026, down 7.0% from a year earlier.

Does Cardiff Oncology pay a dividend?

No. Cardiff Oncology has not paid a cash dividend over the last twelve months.

How has CRDF stock performed over the past year?

Including dividends, CRDF returned -58.9% over the past year, against +11.8% for the S&P 500.

How many CRDF shares are sold short?

12M shares were sold short at the latest FINRA report, 16.58% of the float, or 30.8 days of average trading volume.

Who are Cardiff Oncology's competitors?

Companies most similar to Cardiff Oncology by business, industry and size include PALI, CMPX, ALLR, ONCO, XCUR.

See a number that looks wrong?